Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.

Although phlebotomy and hydroxyurea (HU) are standard first-line therapies for polycythaemia vera (PV), they do not adequately address clonal expansion and chronic inflammation - key drivers of thrombosis, myelofibrosis and mortality. Biomarkers such…

Preview only. Read the full abstract at the source